Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JAB-3068 · 1 trial · 4 indications
Incidence of dose limiting toxicities (DLTs) . A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle with JAB-3068 and JS001.
ORR is defined as the proportion of participants with complete response or partial response (CR+PR).
| Arm | Type | Description |
|---|---|---|
| JAB-3068+PD1 inhibitor Part1 | EXPERIMENTAL | JAB-3068+JS001 dose escalation |
| JAB-3068+PD1 inhibitor Part2 | EXPERIMENTAL | JAB-3068+JS001 dose expansion |
| Name | Type | Description |
|---|---|---|
| JAB-3068 | DRUG | JAB-3068 administrated orally as a tablet. |
| PD1 inhibitor | DRUG | JS001 administrated as an intravenous(IV) infusion. |
Inclusion Criteria: * Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses. * Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF). * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
JAB-3068 is an investigational small molecule being developed for the treatment of advanced solid tumors, including esophageal squamous cell carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
JAB-3068 is being developed by AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol ABBV. The drug is in Phase 1 clinical development for advanced solid tumors.
JAB-3068 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. A Phase 1 trial has been completed, but the drug remains in early-stage clinical testing.
JAB-3068 has one completed Phase 1 clinical trial, identified as NCT04721223, titled "JAB-3068 Activity in Adult Patients With Advanced Solid Tumors." The trial enrolled 12 participants in China and included patients with advanced solid tumors, esophageal squamous cell carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma.
JAB-3068 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information.